Current market catalysts

BMO Capital Initiates Coverage On Amer Sports with Outperform Rating, Announces Price Target of $38

BMO Capital analyst Kelly Crago initiates coverage on Amer Sports (NYSE:AS) with a Outperform rating and announces Price Target of $38.

8-K filing — Daedalus Special Acquisition Corp. (DSACW)

Filed: 2026-09-09 AccNo: 0001213900-26-098215 Size: 281 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

TD Cowen Reiterates Buy on Jersey Mike's Subs, Maintains $26 Price Target

TD Cowen analyst Andrew M. Charles reiterates Jersey Mike's Subs (NYSE:JMKE) with a Buy and maintains $26 price target.

Uber Eats Partners With Wakefern To Offer Grocery Delivery From More Than 375 Northeast Supermarkets

More than 375 stores spanning Wakefern’s family of banner brands, including ShopRite, join the Uber Eats platform, offering delivery of fresh groceries from trusted neighborhood supermarketsUber Technologies, Inc.

Atlas Lithium Announce ~71% Of Neves Project Capex Is Supported By Executed Contracts And Firm Agreements With Selected Execution Partners

In aggregate, these contracted costs are approximately 16% below the corresponding DFS budget, materially de-risking the Project and reinforcing Atlas Lithium's disciplined approach to cost and schedule.Disciplined

Telesat Included In Toronto Stock Exchange's 2026 TSX30

Telesat Corporation (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, is pleased to announce that it has been named to this year’s TSX30. The TMX Group’s flagship annual ranking

8-K filing — Pyxis Oncology, Inc. (PYXS)

Filed: 2026-09-09 AccNo: 0001193125-26-385901 Size: 18 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Meta Platforms shares are trading higher. Yesterday, the company announced the launch of its Muse personal AI agent.

Avino Silver & Gold Mines Included In Toronto Stock Exchange's 2026 TSX30

Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE:ASM)(FSE:GV6) a long-standing silver producer in Mexico, is proud to announce that for the second consecutive year, it has been included in the Toronto Stock

Perma-Pipe Inlt Hldgs Q2 EPS $0.31 Misses $0.55 Estimate, Sales $59.567M Beat $51.000M Estimate

Perma-Pipe Inlt Hldgs (NASDAQ:PPIH) reported quarterly earnings of $0.31 per share which missed the analyst consensus estimate of $0.55 by 43.64 percent. This is a 210 percent increase over earnings of $0.10 per share

SolarEdge Announces Extension Of Infineon Collaboration Into Solid-State Circuit Breaker Technology For 800 VDC Distribution In AI Data Centers, Using Infineon Silicon Carbide JFET Devices

Aris Mining Named To 2026 TSX30

Aris Mining Corporation (Aris Mining or the Company) (TSX: ARIS; NYSE: ARIS) announces that it has been named to the 2026 TSX30, the Toronto Stock Exchange's annual ranking of the 30 top-performing companies listed

Core & Main Q2 Adj. EPS $0.94 Beats $0.92 Estimate, Sales $2.145B Beat $2.136B Estimate

Core & Main (NYSE:CNM) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.92 by 2.17 percent. This is a 8.05 percent increase over earnings of $0.87 per share from the

RXO Says August Truckload Gross Profit Per Load Rose More Than 10% From July, Better Than Prior Outlook; Continues To Expect Q3 Truckload Volume Up Low-To-Mid Single Digit Percentage Year-Over-Year

What's Going On With Nokia Stock Wednesday?

Nokia (NYSE: NOK) stock rose over 2% premarket to $10.91, bucking a market drop. Key technical levels, MACD, and analyst forecasts ahead.

Galmed Pharmaceuticals Announces Rebrand To Eocene And Nasdaq Ticker Change From GLMD To EOCN Effective September 10; Announces Termination Of Yorkville Standby Equity Purchase Agreement Effective September 8

Kazia Therapeutics Doses First Participant In Its Arm A Of PNOC035 Platform To Evaluate Paxalisib In Combination With Gemcitabine Toi Treat Atypical Teratoid/Rhabdoid Tumor

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity

Cognyte Software Q2 Adj. EPS $0.15 Beats $0.09 Estimate, Sales $109.237M Beat $108.616M Estimate

Cognyte Software (NASDAQ:CGNT) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.09 by 66.67 percent. This is a 87.5 percent increase over earnings of $0.08 per share from

8-K filing — Perma-Pipe International Holdings, Inc. (PPIH)

Filed: 2026-09-09 AccNo: 0001437749-26-029909 Size: 320 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

8-K filing — RXO, Inc. (RXO)

Filed: 2026-09-09 AccNo: 0001929561-26-000041 Size: 172 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Core & Main Affirms FY2026 Sales Guidance of $7.800B-$7.900B vs $7.853B Est

Core & Main (NYSE:CNM) affirms FY2026 sales outlook from $7.800 billion-$7.900 billion to $7.800 billion-$7.900 billion vs $7.853 billion estimate.

Context Therapeutics Announces First Patient Dosed In Phase 1 Trial Of Nectin-4 x CD3 Bispecific CT-202 In Urothelial, Colorectal, And Triple-Negative Breast Cancers; Says Initial Phase 1a Data Expected In H2 2027

Cognyte Software Affirms FY2027 Adj EPS Guidance of $0.47 vs $0.45 Est; Narrows FY2027 Sales Guidance from $434.560M-$461.440M to $439.040M-$456.960M vs $446.041M Est

Cognyte Software (NASDAQ:CGNT) affirms FY2027 Adj EPS guidance from $0.47 to $0.47 vs $0.45 analyst estimate. Narrows FY2027 sales outlook from $434.560 million-$461.440 million to $439.040 million-$456.960 million vs

XCharge Says It Received Nasdaq Notification It Regained Compliance With Minimum Bid Price Requirement

8-K filing — Opus Genetics, Inc. (IRD)

Filed: 2026-09-09 AccNo: 0001140361-26-035979 Size: 8 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

StoneX Initiates Coverage On Aptiv with Buy Rating, Announces Price Target of $75

StoneX analyst Mickey Legg initiates coverage on Aptiv (NYSE:APTV) with a Buy rating and announces Price Target of $75.

8-K filing — Soluna Holdings, Inc (SLNHP)

Filed: 2026-09-09 AccNo: 0001493152-26-041870 Size: 265 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — Incannex Healthcare Inc. (IXHL)

Filed: 2026-09-09 AccNo: 0001213900-26-098213 Size: 247 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

8-K filing — Core & Main, Inc. (CNM)

Filed: 2026-09-09 AccNo: 0001856525-26-000091 Size: 3 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

8-K filing — BiomX Inc. (PHGE)

Filed: 2026-09-09 AccNo: 0001213900-26-098212 Size: 210 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits